Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 5,222 Shares of Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 5,222 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $27.30, for a total transaction of $142,560.60. Following the sale, the insider directly owned 139,763 shares of the company’s stock, valued at approximately $3,815,529.90. This trade represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Urogen Pharma Price Performance

URGN opened at $28.18 on Wednesday. Urogen Pharma has a fifty-two week low of $6.73 and a fifty-two week high of $32.37. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -10.25 and a beta of 1.59. The firm has a 50 day simple moving average of $25.06 and a 200 day simple moving average of $22.77.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.01. The firm had revenue of $50.96 million during the quarter, compared to the consensus estimate of $44.83 million. As a group, analysts expect that Urogen Pharma will post -0.98 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. D. Boral Capital reaffirmed a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a research note on Tuesday, March 31st. Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a research note on Tuesday, June 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of Urogen Pharma in a research note on Wednesday, June 3rd. Finally, LADENBURG THALM/SH SH assumed coverage on shares of Urogen Pharma in a research note on Monday, May 11th. They issued a “buy” rating and a $43.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in URGN. AQR Capital Management LLC boosted its holdings in shares of Urogen Pharma by 347.5% in the first quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock valued at $1,262,000 after buying an additional 88,577 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Urogen Pharma by 7.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock valued at $258,000 after buying an additional 1,653 shares during the period. Jane Street Group LLC boosted its holdings in shares of Urogen Pharma by 94.3% in the first quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock valued at $566,000 after buying an additional 24,839 shares during the period. Cetera Investment Advisers acquired a new position in shares of Urogen Pharma in the second quarter valued at approximately $361,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Urogen Pharma by 5.2% in the second quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock valued at $5,348,000 after buying an additional 19,405 shares during the period. Institutional investors and hedge funds own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.